Levamisole in childhood idiopathic nephrotic syndrome: new promises, and advocacy for global access.
Kidney Int
; 105(5): 932-934, 2024 May.
Article
en En
| MEDLINE
| ID: mdl-38642993
ABSTRACT
In the current issue of Kidney International, Sinha et al. present data from an open-label, noninferior, randomized controlled trial comparing 12-months of alternate-day prednisolone, given daily during infection, versus levamisole, in children with frequently relapsing or steroid-dependent nephrotic syndrome. This study suggests that both of these strategies are efficacious and safe. Results of this study should redefine the role of levamisole in future guidelines, and a call for global availability of levamisole should be advocated.
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Levamisol
/
Síndrome Nefrótico
Límite:
Child
/
Humans
Idioma:
En
Revista:
Kidney Int
Año:
2024
Tipo del documento:
Article
Pais de publicación:
Estados Unidos